

John M Matsoukas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/265069/publications.pdf>

Version: 2024-02-01

58
papers

1,270
citations

394421

19
h-index

377865

34
g-index

58
all docs

58
docs citations

58
times ranked

1256
citing authors

#	ARTICLE	IF	CITATIONS
1	Multiple Sclerosis: Immunopathology and Treatment Update. <i>Brain Sciences</i> , 2017, 7, 78.	2.3	197
2	Round and Round we Go: Cyclic Peptides in Disease. <i>Current Medicinal Chemistry</i> , 2006, 13, 2221-2232.	2.4	154
3	Design And Synthesis of a Novel Potent Myelin Basic Protein Epitope 87~99 Cyclic Analogue: Enhanced Stability and Biological Properties of Mimics Render Them a Potentially New Class of Immunomodulators. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 1470-1480.	6.4	62
4	Design of Novel Cyclic Altered Peptide Ligands of Myelin Basic Protein MBP _{83~99} That Modulate Immune Responses in SJL/J Mice. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 3971-3978.	6.4	50
5	Design and Synthesis of a Potent Cyclic Analogue of the Myelin Basic Protein Epitope MBP72-85: Importance of the Ala81 Carboxyl Group and of a Cyclic Conformation for Induction of Experimental Allergic Encephalomyelitis. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 1170-1177.	6.4	48
6	Citrullination of Linear and Cyclic Altered Peptide Ligands from Myelin Basic Protein (MBP _{87~99}) Epitope Elicits a Th1 Polarized Response by T Cells Isolated from Multiple Sclerosis Patients: Implications in Triggering Disease. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 7834-7842.	6.4	47
7	Design and Synthesis of a Cyclic Double Mutant Peptide (cyclo(87~99)[A ⁹¹ ,A ⁹⁶]MBP _{87~99}) Induces Altered Responses in Mice after Conjugation to Mannan: Implications in the Immunotherapy of Multiple Sclerosis. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 214-218.	6.4	40
8	Structure and Function of the Myelin Proteins: Current Status and Perspectives in Relation to Multiple Sclerosis. <i>Current Medicinal Chemistry</i> , 2005, 12, 1569-1587.	2.4	37
9	Mannan-conjugated myelin peptides prime non-pathogenic Th1 and Th17 cells and ameliorate experimental autoimmune encephalomyelitis. <i>Experimental Neurology</i> , 2015, 267, 254-267.	4.1	36
10	One pot synthesis and conformation of N-t-butyloxycarbonyl, O-Phenacyl derivatives of proline and other secondary amino acids. <i>Tetrahedron</i> , 1990, 46, 565-576.	1.9	35
11	Angiotensin as a model for hormone receptor interactions. <i>Bioscience Reports</i> , 1985, 5, 407-416.	2.4	34
12	A double mutation of MBP83~99 peptide induces IL-4 responses and antagonizes IFN- γ responses. <i>Journal of Neuroimmunology</i> , 2008, 200, 77-89.	2.3	34
13	Synthesis and biological activities of angiotensin II, sarilesin, and sarmesin analogs containing Aze or Pip at position 7. <i>Journal of Medicinal Chemistry</i> , 1993, 36, 904-911.	6.4	33
14	Mannosylation of mutated MBP83~99 peptides diverts immune responses from Th1 to Th2. <i>Molecular Immunology</i> , 2008, 45, 3661-3670.	2.2	32
15	Towards immunotherapeutic drugs and vaccines against multiple sclerosis. <i>Acta Biochimica Et Biophysica Sinica</i> , 2008, 40, 636-642.	2.0	30
16	Design and Pharmacology of Peptide Mimetics. <i>Advances in Pharmacology</i> , 1995, 33, 91-141.	2.0	29
17	Microwave-assisted solid-phase peptide synthesis of the 60~110 domain of human pleiotrophin on 2-chlorotriptyl resin. <i>Amino Acids</i> , 2011, 40, 1431-1440.	2.7	29
18	Modulation of Angiogenesis and Progelatinase a by Thrombin Receptor Mimetics and Antagonists. Endothelium: <i>Journal of Endothelial Cell Research</i> , 2001, 8, 195-206.	1.7	28

#	ARTICLE	IF	CITATIONS
19	Rational design, efficient syntheses and biological evaluation of N, N -symmetrically bis-substituted butylimidazole analogs as a new class of potent Angiotensin II receptor blockers. <i>European Journal of Medicinal Chemistry</i> , 2013, 62, 352-370.	5.5	28
20	Regulatory Cell Populations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients: Effect of Disease Activity and Treatment Regimens. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1398.	4.1	26
21	Discovery of a new generation of angiotensin receptor blocking drugs: Receptor mechanisms and in silico binding to enzymes relevant to SARS-CoV-2. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 2091-2111.	4.1	18
22	Properties of myelin altered peptide ligand cyclo(87-99)(Ala91,Ala96)MBP87-99 render it a promising drug lead for immunotherapy of multiple sclerosis. <i>European Journal of Medicinal Chemistry</i> , 2015, 101, 13-23.	5.5	17
23	Understanding the Driving Forces That Trigger Mutations in SARS-CoV-2: Mutational Energetics and the Role of Arginine Blockers in COVID-19 Therapy. <i>Viruses</i> , 2022, 14, 1029.	3.3	17
24	Rational Design and Synthesis of Altered Peptide Ligands based on Human Myelin Oligodendrocyte Glycoprotein 35-55 Epitope: Inhibition of Chronic Experimental Autoimmune Encephalomyelitis in Mice. <i>Molecules</i> , 2014, 19, 17968-17984.	3.8	16
25	Cyclic citrullinated MBP87-99 peptide stimulates T cell responses: Implications in triggering disease. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 528-538.	3.0	16
26	Mannan-MOG35-55 Reverses Experimental Autoimmune Encephalomyelitis, Inducing a Peripheral Type 2 Myeloid Response, Reducing CNS Inflammation, and Preserving Axons in Spinal Cord Lesions. <i>Frontiers in Immunology</i> , 2020, 11, 575451.	4.8	15
27	Receptor Interactions of Angiotensin II and Angiotensin Receptor Blockers- Relevance to COVID-19. <i>Biomolecules</i> , 2021, 11, 979.	4.0	15
28	Mannosylated Linear and Cyclic Single Amino Acid Mutant Peptides Using a Small 10 Amino Acid Linker Constitute Promising Candidates Against Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2015, 6, 136.	4.8	13
29	Cyclic MOG 35 - 55 ameliorates clinical and neuropathological features of experimental autoimmune encephalomyelitis. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 4163-4174.	3.0	11
30	New Advances in Short Peptides: Looking Forward. <i>Molecules</i> , 2022, 27, 3635.	3.8	9
31	Superimposition of potent non-peptide AT1 receptor antagonists with angiotensin II. <i>International Journal of Peptide Research and Therapeutics</i> , 1996, 3, 209-216.	0.1	8
32	Receptor interactions of the position 4 side chains of angiotensin II analogues: Importance of aromatic ring quadrupole. <i>Journal of Molecular Recognition</i> , 1994, 7, 251-256.	2.1	7
33	Interactions of angiotensin II with membranes using a combination of differential scanning calorimetry and ³¹ P NMR spectroscopy. <i>International Journal of Peptide Research and Therapeutics</i> , 1996, 3, 175-180.	0.1	7
34	Biological activity of the novel cyclic angiotensin II analogue [Sar1,Lys3,Glu5]ANG II. <i>International Journal of Peptide Research and Therapeutics</i> , 1996, 3, 191-194.	0.1	7
35	Design and synthesis of a gonadotropin-releasing hormone (GnRH) analogue, [Tyr(OMe)5,d-Glu6,Aze9]GnRH: Receptor binding, gonadotropin release and ovulation studies. <i>International Journal of Peptide Research and Therapeutics</i> , 1996, 3, 257-262.	0.1	7
36	Cyclization of PLP139-151 peptide reduces its encephalitogenic potential in experimental autoimmune encephalomyelitis. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 2221-2228.	3.0	7

#	ARTICLE	IF	CITATIONS
37	The Long Road of Immunotherapeutics against Multiple Sclerosis. <i>Brain Sciences</i> , 2020, 10, 288.	2.3	7
38	Modulation of Angiogenesis and Progelatinase a by Thrombin Receptor Mimetics and Antagonists. <i>Endothelium: Journal of Endothelial Cell Research</i> , 2001, 8, 195-206.	1.7	7
39	The Use of Electrochemical Voltammetric Techniques and High-Pressure Liquid Chromatography to Evaluate Conjugation Efficiency of Multiple Sclerosis Peptide-Carrier Conjugates. <i>Brain Sciences</i> , 2020, 10, 577.	2.3	6
40	Myelin Peptideâ€“Mannan Conjugate Multiple Sclerosis Vaccines: Conjugation Efficacy and Stability of Vaccine Ingredient. <i>Vaccines</i> , 2021, 9, 1456.	4.4	6
41	A comparative SAR study of thrombin receptor derived non peptide mimetics: Importance of phenyl/guanidino proximity for activity. <i>Amino Acids</i> , 1998, 15, 211-220.	2.7	5
42	Advances in Multiple Sclerosis Researchâ€“Series I. <i>Brain Sciences</i> , 2020, 10, 795.	2.3	5
43	Novel Approaches in the Immunotherapy of Multiple Sclerosis: Cyclization of Myelin Epitope Peptides and Conjugation with Mannan. <i>Brain Sciences</i> , 2021, 11, 1583.	2.3	5
44	Influence of sarmesin on some dopamine-related types of behaviour. <i>International Journal of Peptide Research and Therapeutics</i> , 1996, 3, 185-190.	0.1	4
45	Synthesis and activities of cyclic thrombin-receptor-derived peptide analogues of the Ser42-Phe-Leu-Leu-Arg46 motif sequence containing d-Phe and/or d-Arg. <i>International Journal of Peptide Research and Therapeutics</i> , 1996, 3, 233-240.	0.1	4
46	Design of Linear and Cyclic Mutant Analogues of Dirucotide Peptide (MBP82â€“98) against Multiple Sclerosis: Conformational and Binding Studies to MHC Class II. <i>Brain Sciences</i> , 2018, 8, 213.	2.3	4
47	Nmr and Mass Spectroscopic Studies of the Competitive-Angiotensin II Antagonist â€œSarmesinâ€: <i>Spectroscopy Letters</i> , 1988, 21, 477-491.	1.0	3
48	Synthesis and biological activities of angiotensin II and Sarmesin analogues containing cyclohexylalanine. <i>International Journal of Peptide and Protein Research</i> , 1991, 37, 21-26.	0.1	3
49	Transdermal Delivery of AT1 Receptor Antagonists Reduce Blood Pressure and Reveal a Vasodilatory Effect on Kidney Blood Vessels. <i>Current Molecular Pharmacology</i> , 2018, 11, 226-236.	1.5	3
50	¹³ C NMR of Some Malic Acid Derivatives. <i>Spectroscopy Letters</i> , 1983, 16, 933-943.	1.0	2
51	Design and synthesis of potent tyr(OMe) ⁵ -gonadotropin-releasing hormone (GnRH) analogues with modifications at positions 6, 9 and 10. <i>International Journal of Peptide Research and Therapeutics</i> , 1998, 5, 305-315.	0.1	2
52	The Human Myelin Proteome and Sub-Metalloproteome Interaction Map: Relevance to Myelin-Related Neurological Diseases. <i>Brain Sciences</i> , 2022, 12, 434.	2.3	2
53	Advances in antihypertensive therapy: Non-peptide angiotensin II receptor antagonists as potent therapeutic agents. <i>International Journal of Peptide Research and Therapeutics</i> , 1996, 3, 169-174.	0.1	1
54	Inhibition of TRAP-induced angiogenesis by the tripeptide Phe-Pro-Arg, a thrombin-receptor-derived peptide analogue. <i>International Journal of Peptide Research and Therapeutics</i> , 1996, 3, 227-232.	0.1	1

#	ARTICLE	IF	CITATIONS
55	Title is missing!. International Journal of Peptide Research and Therapeutics, 1998, 5, 305-315.	0.1	1
56	Influence of sarmesin on the cardiac and vascular actions of angiotensin II. International Journal of Peptide Research and Therapeutics, 1996, 3, 181-184.	0.1	0
57	Design and synthesis of potent cyclic analogues and mimetics of myelin basic protein epitope MBP87-99 for suppression of experimental allergic encephalomyelitis (EAE). Expert Opinion on Therapeutic Targets, 1998, 2, 31-32.	1.0	0
58	Immunoexpression patterns for Hypoxia-inducible Factor-1 α and von Hippel-Lindau protein, in relation to Hsp90, of human brain tumors. Histology and Histopathology, 2016, 31, 535-46.	0.7	0